

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan Golz, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP03/02414

Title: Diagnostics and Therapeutics for Diseases Associated with Homo Sapiens Formyl Peptide Receptor-Like 2

**MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Susan M. Pellegrino
Reg. No.: 48,972
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-6450
Facsimile: (203) 812-6459

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Serial No.		Art Unit		Filing Date		Atty. Docket No. 10/508765				
INFORMATION DISCLOSURE CITATION				Applicant(s) Stefan GOLZ, et al.										
U.S. PATENT DOCUMENTS														
*		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS														
*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION YES NO	
	F1	0	1	6	8	8	3	9	20/09/01	WO				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)														
	R1	Betten, A., et al., "A proinflammatory peptide from <i>Helicobacter pylori</i> activates monocytes to induce lymphocyte dysfunction and apoptosis", J. Clin. Invest., 108(8): 1221-1228 (October 2001)												
	R2	Keitoku, M., et al., "FMLP Actions and its Binding Sites in Isolated Human Coronary Arteries", J. Mol. Cell Cardiol., 29(3): 881-894 (1997)												
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														